Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Blood tests and patient surveys could improve bile duct cancer monitoring

NCT ID NCT07454486

Knowledge-focused Sponsor: Aarhus University Hospital Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study aims to learn if blood tests for cancer DNA (ctDNA) and patient-reported quality of life can help doctors predict how bile duct cancer will progress and whether treatments are working. Researchers will collect blood samples and surveys from 300 patients with curable or incurable bile duct cancer. The goal is to find better ways to monitor the disease than standard CT scans, which can be unreliable for this cancer type.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 300 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Mar 2026

An estimate. Start dates often move.

Expected to finish

Dec 2031

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Study participants will be selected from adult patients with histopathologically verified BTC-or those defined as having BTC by a Multidisciplinary Team (MDT) conference-who are candidates for curative (including downstaging and adjuvant) or palliative treatment and who have no contraindications to blood sampling. Patients are identified in routine clinical practice and referred for oncological management. Patients will be recruited prospectively as they are seen in daily clinical care at participating oncology centers. Eligible individuals must be able to provide written and oral informed consent. The population therefore includes patients across the disease spectrum (localized, locally advanced, or metastatic BTC) undergoing standard-of-care treatments such as surgery, systemic therapy, interventional procedures, or surveillance, with no alteration of therapy due to study participation.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Histopathologically verified biliary tract cancer (BTC) and/or Multidisciplinary Team (MDT) conference decision to define the patient as suffering from BTC. * Eligible for curative, adjuvant, or palliative oncological treatment. * Age ≥ 18 years. * Written and oral consent. Exclusion Criteria: * Other malignant diseases within 5 years of BTC diagnosis, excluding early-stage non-melanoma skin cancer and carcinoma in situ of the cervix. * Conditions that prohibit blood sampling. * Known or suspected non-compliance.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Biliary tract cancer (BTC) are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

bile duct adenocarcinoma biliary tract cancer Biliary Tract Neoplasms cholangiocarcinoma extrahepatic bile duct carcinoma gallbladder cancer gallbladder neoplasm hilar cholangiocarcinoma intrahepatic cholangiocarcinoma neoplasm Neoplasm, Residual perihilar intrahepatic cholangiocarcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Biliary tract cancer (BTC) Biliary tract cancer (CCA) Biliary tract cancers (BTC) Cholangiocarcinoma Cholangiocarcinoma metastatic Cholangiocarcinoma non-resectable Cholangiocarcinoma of the bile duct Cholangiocarcinoma resectable Cholangiocarcinoma, extrahepatic Cholangiocarcinoma, hilar Cholangiocarcinoma, intrahepatic Cholangiocarcinoma, perihilar Cholangiocarcinoma; liver Gall bladder cancer

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Aarhus University Hospital

    Aarhus, 8220, Denmark

More trials for these conditions

Other studies related to the condition(s) this trial covers.